Compare Crispr Therapeutics AG (CRSP) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Motorola Solutions Inc — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Motorola Solutions Inc trades at $421.22 (market cap $68.67B). The key difference: Motorola Solutions Inc is far larger — about 13.8× Crispr Therapeutics AG's market cap, and Motorola Solutions Inc pays a 1.17% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MSI | |
|---|---|---|
Market Cap | $4.97B | $68.67B |
Sector | Health | Technology |
52-Week High | $76.78 | $490.30 |
52-Week Low | $44.34 | $363.83 |
Enterprise Value | $3.32B | $77.38B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Motorola Solutions (MSI) trades at $418.06, down 1.14% today, with a neutral technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $11.68B and net income of $2.15B, supported by a 99.88% ROE. Recent developments include the $1.5B D-Fend acquisition and AI expansion for emergency response systems, positioning MSI for growth in public safety technology.
MSI presents a compelling investment case with analyst consensus price target of $512.33 (22.5% upside) and 71% buy ratings. Strong profitability and strategic AI investments are offset by high valuation multiples (P/E 33.71) and negative cash flow from significant acquisitions. Key risks include integration challenges from recent deals and competitive pressure in the public safety sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
